Navigation Links
Vermillion to Host Live Roundtable Discussion With Principal Investigator of OVA1(TM) Submission
Date:7/11/2008

- Conference Call to Occur on Tuesday, July 15 at 4:30 p.m. Eastern -

FREMONT, Calif., July 11 /PRNewswire-FirstCall/ -- Vermillion, Inc. (Nasdaq: VRML), a molecular diagnostics company, will host a roundtable teleconference to discuss the recent OVA1 submission. Dr. Fred Ueland, M.D., Principal Investigator on the submission and Associate Professor of Gynecologic Oncology at the University of Kentucky, will be the keynote speaker of the roundtable.

Vermillion's ovarian tumor triage test utilizes a panel of biomarkers designed to help identify women at high risk of having cancer so that they can be referred directly to a gynecologic oncologist for their initial surgery. While the vast majority of these tumors are benign, studies show that women with ovarian cancer have improved median and overall survival when the surgery is performed by a gynecologic oncologist.

About Vermillion's Ovarian Cancer Diagnostic Program

In addition to developing a diagnostic test designed to distinguish between benign and malignant pelvic masses, Vermillion has a broad program of ovarian cancer diagnostic tests in development. Studies are underway to verify the capability of such tests to detect early-stage ovarian cancer, predict prognosis and recurrence, and identify women considered at high-risk for the disease.

Vermillion's comprehensive diagnostic development program is being conducted with several leading collaborators at The Johns Hopkins School of Medicine, The University of Texas M.D. Anderson Cancer Center, Rigshospitalet (Copenhagen), and the University of Kentucky.

Conference Call Information

To access the live conference call via phone, dial (888) 389-6569 from the United States and Canada or (706) 643-2819 internationally. The conference ID is 21388502. Please dial-in approximately ten minutes prior to the start of the call. Additionally, you may access the live and subsequently archived web cast of the conference call from the Investor Relations section of the Company's website at http://www.vermillion.com. Please connect to the web site at least 15 minutes prior to the call to allow for any software download that may be necessary.

A telephone replay will be available beginning approximately two hours after the call through July 22, 2008, and may be accessed by dialing (800) 633-8284 from the United States and Canada or (+1 402) 977-9140 internationally. The replay passcode is 21388502. An archived replay of the web cast will be available until the next quarterly call.

About Vermillion

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Vermillion is based in Fremont, California. Additional information about Vermillion can be found on the Web at http://www.vermillion.com.

Forward Looking Statements

This news release contains forward-looking statements that involve significant risks and uncertainties, including the risks and uncertainties discussed in Vermillion's Form 10-K for the year ended December 31, 2007, and Vermillion's periodic reports on Form 10-Q and Form 8-K. Vermillion is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise. Forward-looking statements cannot be guaranteed and actual results may differ materially from Vermillion's current expectations. You are encouraged to read Vermillion's reports filed with the U.S. Securities and Exchange Commission, available at http://www.sec.gov.


'/>"/>
SOURCE Vermillion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock
2. Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease
3. Vermillion, Inc. Announces Receipt Of Notice Of Compliance From Nasdaq
4. Vermillion to Webcast Presentation at the Acumen BioFin 9th Annual Healthcare Conference, November 5-7, New York
5. Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests
6. Vermillion Receives NASDAQ Notice of Non-Compliance
7. Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk
8. Vermillion Announces Effectiveness of Reverse Stock Split
9. Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones
10. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
11. Vermillion Biomarker Panel Potential Aid in the Diagnosis of Peripheral Artery Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... Board of Directors has approved the payment of a quarterly ... The cash dividend of $0.24 per share ... stockholders of record as of the close of business on ... approval of the Board of Directors and may be adjusted ...
(Date:5/22/2016)... ... May 22, 2016 , ... Doctors in Rome say micronutrients found ... cancer, malignant mesothelioma. Surviving Mesothelioma has just posted an article on the new research. ... Rome’s Department of Clinical Sciences and Translational Medicine evaluated more than 150 studies on ...
(Date:5/19/2016)... ... May 19, 2016 , ... Anton Paar USA, located in Ashland, Virginia ... is complete. The new structure adds a third office building to the current facilities. ... purchased 2.4 acres of land, along with office space adjacent to the previous main ...
(Date:5/19/2016)... MADRID , May 19, 2016 ... di una sessione orale durante il 52 ° ... (abstract n. 8006)    - Le conclusioni ... quanto riguarda i pazienti trattati, di cui il 90% presenta ... di sei mesi o più. Il settantadue per cento dei ...
Breaking Biology Technology:
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:4/26/2016)... and LONDON , April 26, ... of EdgeVerve Systems, a product subsidiary of Infosys ... announced a partnership to integrate the Onegini mobile ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... customers enhanced security to access and transact across ...
(Date:4/14/2016)... Israel , April 14, 2016 ... Authentication and Malware Detection, today announced the appointment of ... assumed the new role. Goldwerger,s leadership appointment ... on the heels of the deployment of its platform ... BioCatch,s behavioral biometric technology, which discerns unique cognitive and ...
Breaking Biology News(10 mins):